Back to top
more

Charles River Laboratories International, Inc. (CRL)

(Real Time Quote from BATS)

$320.46 USD

320.46
247,277

-2.25 (-0.70%)

Updated May 18, 2021 01:07 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (171 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for CRL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Charles River Laboratories International, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 228 238 195 164 118
Receivables 618 514 472 430 364
Notes Receivable 0 0 0 0 0
Inventories 186 161 128 115 96
Other Current Assets 169 109 102 118 79
Total Current Assets 1,201 1,021 898 827 657
Net Property & Equipment 1,124 1,044 933 782 756
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 38 45 23 23 29
Intangibles 1,875 1,616 1,320 873 862
Deposits & Other Assets 1,074 826 682 426 409
Total Assets 5,491 4,693 3,856 2,930 2,712
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 122 112 66 78 68
Current Portion Long-Term Debt 50 39 31 31 27
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 357 298 244 191 178
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 310 262 216 164 156
Total Current Liabilities 840 710 558 464 430
Mortgages 0 0 0 0 0
Deferred Taxes/Income 217 167 144 90 56
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,930 1,850 1,637 1,114 1,208
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 205 183 179 199 165
Minority Interest (Liabilities) 26 29 19 17 15
Total Liabilities 3,373 3,055 2,536 1,883 1,873
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 0 0 1 1
Capital Surplus 1,628 1,532 1,448 2,560 2,477
Retained Earnings 625 280 42 289 165
Other Equity -135 -175 -170 -142 -251
Treasury Stock 0 0 0 1,660 1,553
Total Shareholder's Equity 2,118 1,638 1,320 1,047 839
Total Liabilities & Shareholder's Equity 5,491 4,693 3,856 2,930 2,712
Total Common Equity 2,118 1,638 1,320 1,047 839
Shares Outstanding 49.70 48.90 48.20 47.30 47.30
Book Value Per Share 42.62 33.49 27.38 22.14 17.74

Fiscal Year End for Charles River Laboratories International, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Assets          
Cash & Equivalents 465 228 243 402 372
Receivables 611 618 572 533 542
Notes Receivable 0 0 0 0 0
Inventories 194 186 181 168 163
Other Current Assets 154 169 144 132 131
Total Current Assets 1,423 1,201 1,140 1,235 1,208
Net Property & Equipment 1,117 1,124 1,037 1,028 1,033
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 35 38 40 43 43
Intangibles 1,974 1,875 1,848 1,810 1,812
Deposits & Other Assets 1,062 1,074 980 957 950
Total Assets 5,809 5,491 5,213 5,241 5,202
Liabilities & Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 127 122 97 83 103
Current Portion Long-Term Debt 3 50 48 54 48
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 363 357 342 312 253
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 310 310 300 279 288
Total Current Liabilities 803 840 787 728 691
Mortgages 0 0 0 0 0
Deferred Taxes/Income 207 217 202 202 197
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,202 1,930 1,968 2,207 2,327
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 207 184 176 174
Minority Interest (Liabilities) 28 26 24 24 24
Total Liabilities 3,621 3,373 3,312 3,484 3,546
Shareholders Equity 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,660 1,628 1,614 1,590 1,563
Retained Earnings 687 625 501 399 331
Other Equity -123 -135 -191 -209 -215
Treasury Stock 36 0 24 24 24
Total Shareholder's Equity 2,188 2,118 1,901 1,757 1,656
Total Liabilities & Shareholder's Equity 5,809 5,491 5,213 5,241 5,202
Total Common Equity 2,188 2,118 1,901 1,757 1,656
Shares Outstanding 50.20 49.70 49.70 49.60 49.40
Book Value Per Share 43.59 42.62 38.26 35.42 33.51